HK Stock Market Move | Genscript Biotech (01548) rose nearly 9% in morning trading; CARVYKTI third-quarter sales were $710 million, continuing to ramp up quarter over quarter.

Genscript Biotech (01548) rose nearly 9% in morning trading. As of press time, it was up 7.18% at HK$35.82, with turnover of HK$386 million. On the news front, Genscript Biotech recently announced that Legend Biotech disclosed that CARVYKTI's net trade sales in the third quarter of 2026 were approximately US$710 million. Combined with first-half revenue of US$1.254 billion, Carvykti's cumulative sales in the first three quarters totaled approximately US$1.964 billion, up 47.4% year over year. Looking at the quarterly trend, the product's Q1 sales were US$597 million, Q2 reached US$657 million, and Q3 climbed further to US$710 million, continuing to ramp up quarter over quarter. It is worth noting that on September 16, Genscript Biotech announced a collaboration with Eli Lilly's AIDD collaboration platform Lilly TuneLab. Under the agreement, the company will provide wet-lab services to TuneLab participating companies, helping them rapidly generate experimental data, convert AI predictions into biological validation data, and accelerate candidate drug evaluation. JPMorgan said this move is a strategic entry point to access an ecosystem of more than 100 biotech clients and close the loop between dry and wet lab experiments.